or Try an Advanced Search...

    Technical Analysis for ALLR - Allarity Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.62 6.21% 0.04
    ALLR closed up 6.21 percent on Friday, May 31, 2024, on 1.8 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ALLR trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    Doji - Bearish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Narrow Range Bar Range Contraction 6.21%
    Doji - Bullish? Reversal 6.21%
    Wide Bands Range Expansion 6.21%
    Oversold Stochastic Weakness 6.21%
    Stochastic Buy Signal Bullish 4.34%
    Narrow Range Bar Range Contraction 4.34%
    Older End-of-Day Signals for ALLR ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 2 days ago
    Possible Pocket Pivot 2 days ago
    Down 1% 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    10 DMA Support 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ALLR Chart by TradingView
    Basic chart:

    Profile

    Allarity Therapeutics, Inc. Description

    Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Liposome Doxorubicin

    Is ALLR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 20 Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
    May 15 Allarity Therapeutics reports Q1 GAAP EPS of -$22.14
    May 14 Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
    May 7 All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
    May 7 Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
    May 6 Allarity exceeds Nasdaq's minimum equity requirement
    May 6 Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
    May 2 Allarity rallies on conclusion of mid-stage trial for its ovarian cancer treatment after showing clinical benefit
    May 2 Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
    Apr 29 Allarity regains compliance with NASDAQ minimum bid price requirement
    See more ALLR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 269.8
    52 Week Low 0.55
    Average Volume 4,867,742
    200-Day Moving Average 10.65
    50-Day Moving Average 2.25
    20-Day Moving Average 0.70
    10-Day Moving Average 0.60
    Average True Range 0.21
    RSI (14) 20.63
    ADX 22.07
    +DI 30.81
    -DI 21.75
    Chandelier Exit (Long, 3 ATRs) 2.82
    Chandelier Exit (Short, 3 ATRs) 1.19
    Upper Bollinger Bands 0.93
    Lower Bollinger Band 0.46
    Percent B (%b) 0.33
    BandWidth 66.42
    MACD Line -0.45
    MACD Signal Line -0.58
    MACD Histogram 0.1292
    Fundamentals Value
    Market Cap 3.63 Million
    Num Shares 5.89 Million
    EPS 2625.43
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 2.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.78
    Resistance 3 (R3) 0.78 0.73 0.75
    Resistance 2 (R2) 0.73 0.69 0.73 0.74
    Resistance 1 (R1) 0.67 0.66 0.70 0.67 0.74
    Pivot Point 0.62 0.62 0.64 0.62 0.62
    Support 1 (S1) 0.56 0.58 0.59 0.56 0.50
    Support 2 (S2) 0.51 0.55 0.51 0.49
    Support 3 (S3) 0.45 0.51 0.48
    Support 4 (S4) 0.45